Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.31 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5314786 | 0.88 | ERCC1 (0.35) | ERCC1FEN1ERCC4 | |
| SCHEMBL2206140 | 0.85 | KDM4C (0.32) | KDM4CRNASEH1 | |
| SCHEMBL2207964 | 0.78 | CYP2C9 (0.47) | — | |
| SCHEMBL13672437 | 0.74 | NPSR1 (0.36) | NPSR1KDM4CRNASEH1ERCC1FEN1 | |
| SCHEMBL2202249 | 0.73 | ALDH1A1 (0.43) | NPSR1RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL22079303 | 0.71 | NPSR1 (0.39) | NPSR1KDM4CRNASEH1ERCC1FEN1 | |
| SCHEMBL12529315 | 0.71 | ALDH1A1 (0.36) | NPSR1 | |
| SCHEMBL13672439 | 0.70 | ALDH1A1 (0.38) | NPSR1ERCC1FEN1ERCC4 | |
| SCHEMBL22079305 | 0.69 | ADORA2A (0.40) | NPSR1RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL2204212 | 0.67 | CYP2C9 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | REV1, CDK9, INTS9 | NPSR1 3257/4885KDM4C 1787/4885RNASEH1 126/4885 |
| US-20090253681-A1 | HIV Integrase Inhibitors | REV1, INTS9, H1-10 | NPSR1 3466/4885KDM4C 2187/4885RNASEH1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.